About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Ldlr
low density lipoprotein receptor
MGI:96765
181 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Agtr1atm1Uky/Agtr1atm1Uky
Ldlrtm1Her/Ldlrtm1Her
Tg(Tagln-cre)1Her/0
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N * SJL 		normal cardiovascular system phenotype J:170230
Agtr1atm1Uky/Agtr1atm1Uky
Ldlrtm1Her/Ldlrtm1Her
Tg(Tek-cre)12Flv/0
involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6N 		abnormal aorta elastic fiber morphology J:170230
abnormal ascending aorta morphology J:170230
decreased aorta wall thickness J:170230
decreased susceptibility to induced aneurysm formation J:170230
Agtr1atm1Unc/Agtr1atm1Unc
Ldlrtm1Her/Ldlrtm1Her
B6.129-Ldlrtm1Her Agtr1atm1Unc 		decreased susceptibility to induced aneurysm formation J:170230
Aldoctm1.1(KOMP)Vlcg/Aldoctm1.1(KOMP)Vlcg
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6J * C57BL/6N 		decreased body weight J:346664
decreased circulating cholesterol level J:346664
decreased circulating LDL cholesterol level J:346664
decreased circulating triglyceride level J:346664
decreased liver cholesterol level J:346664
decreased liver triglyceride level J:346664
decreased liver weight J:346664
Alox15tm1Fun/Alox15tm1Fun
Ldlrtm1Her/Ldlrtm1Her
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 		decreased susceptibility to atherosclerosis J:86385
Angptl3tm1Lex/Angptl3tm1Lex
Ldlrtm1Her/Ldlrtm1Her
involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6 		decreased circulating cholesterol level J:149912
decreased circulating triglyceride level J:149912
Apoa1tm1Unc/Apoa1tm1Unc
Ldlrtm1Her/Ldlrtm1Her
B6.129-Ldlrtm1Her Apoa1tm1Unc 		abnormal adrenal gland morphology J:85174
abnormal adrenal gland zona fasciculata morphology J:85174
abnormal liver morphology J:85174
decreased cholesterol level J:85174
decreased circulating cholesterol level J:85174
decreased circulating HDL cholesterol level J:85174
decreased circulating LDL cholesterol level J:85174
decreased circulating VLDL cholesterol level J:85174
decreased liver cholesterol level J:85174
increased circulating triglyceride level J:85174
increased pruritus J:85174
skin lesions J:85174
spontaneous skin ulceration J:85174
thick dermal layer J:85174
xanthoma J:85174
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6 		abnormal eye electrophysiology J:136142
abnormal retina pigment epithelium morphology J:136142
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6J 		abnormal aorta bulb morphology J:227165
abnormal heart ventricles weight J:227165
aortic valve stenosis J:227165
decreased cardiac muscle contractility J:227165
increased cardiac output J:227165
increased cardiac stroke volume J:227165
increased circulating cholesterol level J:227165
increased circulating insulin level J:227165
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
Lepob/Lepob
involves: 129S7/SvEvBrd * C57BL/6 		abnormal circulating cholesterol level J:133453
atherosclerotic lesions J:133453
decreased circulating HDL cholesterol level J:133453
hypertension J:133453
increased circulating cholesterol level J:133453
increased circulating free fatty acids level J:133453
increased circulating insulin level J:133453
increased circulating LDL cholesterol level J:133453
increased circulating triglyceride level J:133453
obese J:133453
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
Tg(Ins-Igf2)1Fbos/?
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL 		abnormal aorta bulb morphology J:227165
abnormal aortic valve morphology J:227165
abnormal cardiovascular system physiology J:227165
abnormal fasting circulating glucose level J:227165
abnormal heart left ventricle morphology J:227165
abnormal heart ventricles weight J:227165
aortic valve stenosis J:227165
aortitis J:227165
calcified aortic valve J:227165
cardiac fibrosis J:227165
cardiac hypertrophy J:227165
decreased cardiac muscle contractility J:227165
heart left ventricle hypertrophy J:227165
increased cardiac output J:227165
increased cardiac stroke volume J:227165
increased circulating cholesterol level J:227165
increased circulating insulin level J:227165
small aortic valve J:227165
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
Tg(Ins-Igf2)1Fbos/?
involves: 129S7/SvEvBrd * C57BL/6 * SJL 		atherosclerotic lesions J:141333
impaired glucose tolerance J:141333
increased circulating glucose level J:141333
increased circulating insulin level J:141333
Apobec1tm1Chan/Apobec1tm1Chan
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd 		abnormal circulating cholesterol level J:48202
decreased circulating triglyceride level J:48202
increased circulating cholesterol level J:48202
increased circulating triglyceride level J:48202
Apobec1tm1Ddsn/Apobec1tm1Ddsn
Fggtm1Fjc/Fggtm1Fjc
Ldlrtm1Her/Ldlrtm1Her
B6.129-Fggtm1Fjc Apobec1tm1Ddsn Ldlrtm1Her 		abnormal blood coagulation J:132734
atherosclerotic lesions J:132734
increased circulating LDL cholesterol level J:132734
postnatal lethality, incomplete penetrance J:135942
Apobec1tm1Ddsn/Apobec1tm1Ddsn
Ldlrtm1Her/Ldlrtm1Her
B6.129-Apobec1tm1Ddsn Ldlrtm1Her 		abnormal blood coagulation J:132734
atherosclerotic lesions J:132734
decreased partial thromboplastin time J:132734
decreased prothrombin time J:132734
increased circulating antithrombin level J:132734
increased circulating LDL cholesterol level J:132734
increased circulating prothrombin level J:132734
Apobec1tm1Ddsn/Apobec1tm1Ddsn
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		atherosclerotic lesions J:49125
increased circulating cholesterol level J:49125
increased circulating LDL cholesterol level J:49125
increased circulating triglyceride level J:49125
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 		abnormal lipid homeostasis J:67282
decreased susceptibility to hyperlipidemia J:67282
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6 		normal homeostasis/metabolism phenotype J:117317
increased circulating cholesterol level J:117317
increased circulating HDL cholesterol level J:117317
increased circulating LDL cholesterol level J:117317
increased circulating triglyceride level J:117317
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		atherosclerotic lesions J:129557
increased susceptibility to atherosclerosis J:129557
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL 		abnormal circulating enzyme level J:90547
abnormal circulating protein level J:90547
decreased circulating cholesterol level J:90547
decreased circulating LDL cholesterol level J:90547
decreased circulating triglyceride level J:90547
decreased circulating VLDL cholesterol level J:90547
increased circulating cholesterol level J:117317
increased circulating factor VIII level J:90547, J:117317
increased circulating HDL cholesterol level J:117317
increased circulating LDL cholesterol level J:117317
increased circulating triglyceride level J:117317
increased circulating von Willebrand factor level J:90547
increased susceptibility to atherosclerosis J:90547
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		increased circulating cholesterol level J:59491
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		abnormal impulse conducting system conduction J:95598
abnormal response to cardiac infarction J:95598
abnormal ST segment J:95598
abnormal synapse morphology J:43043
abnormal thrombosis J:95598
atherosclerotic lesions J:95598
decreased circulating troponin level J:95598
decreased myocardial infarct size J:95598
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal circulating lipid level J:146721
amyloid beta deposits J:146721
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal circulating lipid level J:146721
amyloid beta deposits J:146721
increased circulating cholesterol level J:146721
increased circulating triglyceride level J:146721
Asgr2tm1Her/Asgr2tm1Her
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6 		abnormal lipid homeostasis J:21380
Ath37CAST/Ei/Ath37CAST/Ei
Ldlrtm1Her/Ldlrtm1Her
involves: CAST/Ei * C57BL/6J 		decreased susceptibility to atherosclerosis J:109792
Ath38CAST/Ei/Ath38CAST/Ei
Ldlrtm1Her/Ldlrtm1Her
involves: CAST/Ei * C57BL/6J 		decreased susceptibility to atherosclerosis J:109792
Ccl2tm1Rol/Ccl2tm1Rol
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		decreased susceptibility to atherosclerosis J:75837
increased circulating triglyceride level J:75837
increased circulating VLDL cholesterol level J:75837
Cd1d1tm1Luc/Cd1d1tm1Luc
Ldlrtm1Her/Ldlrtm1Her
B6.129S-Cd1d1tm1Luc Ldlrtm1Her 		atherosclerotic lesions J:110061
decreased circulating VLDL cholesterol level J:110061
increased susceptibility to atherosclerosis J:110061
Crotem1Akw/Crotem1Akw
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Crotem1Akw Ldlrtm1Her 		abnormal artery morphology J:331161
blood vessel inflammation J:331161
normal skeleton phenotype J:331161
Crptm1Hjf/Crptm1Hjf
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Crptm1Hjf Ldlrtm1Her 		atherosclerotic lesions J:170409
decreased circulating LDL cholesterol level J:170409
decreased circulating VLDL cholesterol level J:170409
increased circulating cholesterol level J:170409
increased circulating triglyceride level J:170409
Ctsstm1Hap/Ctsstm1Hap
Ldlrtm1Her/Ldlrtm1Her
B6.129S-Ctsstm1Hap Ldlrtm1Her 		abnormal leukocyte migration J:82520
decreased circulating cholesterol level J:82520
decreased circulating LDL cholesterol level J:82520
decreased susceptibility to atherosclerosis J:82520
vascular smooth muscle hypoplasia J:82520
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
Ldlrtm1Her/Ldlr+
involves: B6.129S4-Cx3cl1tm1Sgs * B6.129S7-Ldlrtm1Her/J 		decreased circulating cholesterol level J:95279
decreased circulating LDL cholesterol level J:95279
decreased susceptibility to atherosclerosis J:95279
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
Ldlrtm1Her/Ldlrtm1Her
involves: B6.129S4-Cx3cl1tm1Sgs * B6.129S7-Ldlrtm1Her/J 		decreased circulating cholesterol level J:95279
decreased circulating LDL cholesterol level J:95279
decreased susceptibility to atherosclerosis J:95279
impaired macrophage chemotaxis J:95279
Cxcl1tm1Wabo/Cxcl1tm1Wabo
Ldlrtm1Her/Ldlrtm1Her
involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 		atherosclerotic lesions J:107325
decreased susceptibility to atherosclerosis J:107325
Ddr1tm1Wfv/Ddr1tm1Wfv
Ldlrtm1Her/Ldlrtm1Her
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ 		atherosclerotic lesions J:149015
decreased macrophage cell number J:149015
Del(11Cxcl16-Zmynd15)1Ifc/Del(11Cxcl16-Zmynd15)1Ifc
Ldlrtm1Her/Ldlrtm1Her
B6.129S-Ldlrtm1Her Del(11Cxcl16-Zmynd15)1Ifc 		atherosclerotic lesions J:123851
increased apoptosis J:123851
Esr1tm1.1Mma/Esr1tm1.1Mma
Ldlrtm1Her/Ldlrtm1Her
involves: 129S2/SvPas * 129S7/SvEvBrd 		abnormal response/metabolism to endogenous compounds J:144952
increased susceptibility to atherosclerosis J:144952
Esr1tm1Arnal/Esr1tm1Arnal
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd 		abnormal response/metabolism to endogenous compounds J:144952
increased susceptibility to atherosclerosis J:144952
Fmo3em1Jmbn/Fmo3em1Jmbn
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6 		abnormal beige fat cell morphology J:254352
decreased susceptibility to diet-induced obesity J:254352
decreased total body fat amount J:254352
Gpr132tm1Witt/Gpr132tm1Witt
Ldlrtm1Her/Ldlrtm1Her
B6.129-Ldlrtm1Her Gpr132tm1Witt 		atherosclerotic lesions J:100498
decreased macrophage apoptosis J:100498
Hhipl1tm1a(KOMP)Wtsi/Hhipl1tm1a(KOMP)Wtsi
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6J * C57BL/6N 		decreased susceptibility to atherosclerosis J:280707
Icam1tm1Jcgr/Icam1tm1Jcgr
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd 		increased neutrophil cell number J:69597
Icam1tm1Jcgr/Icam1tm1Jcgr
Ldlrtm1Her/Ldlrtm1Her
Vcam1tm1Dmil/Vcam1tm1Dmil
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		decreased circulating cholesterol level J:69597
decreased susceptibility to atherosclerosis J:69597
increased leukocyte cell number J:69597
increased lymphocyte cell number J:69597
increased monocyte cell number J:69597
increased neutrophil cell number J:69597
Ifngtm1Ts/Ifngtm1Ts
Ldlrtm1Her/Ldlrtm1Her
B6.129S7-Ldlrtm1Her Ifngtm1Ts 		atherosclerotic lesions J:103072
increased T cell number J:103072
Ins2Akita/Ins2Akita
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Ins2Akita Ldlrtm1Her 		decreased body weight J:174983
decreased circulating insulin level J:174983
hyperglycemia J:174983
impaired glucose tolerance J:174983
increased circulating cholesterol level J:174983
increased circulating HDL cholesterol level J:174983
increased circulating LDL cholesterol level J:174983
increased circulating triglyceride level J:174983
increased circulating VLDL cholesterol level J:174983
increased susceptibility to atherosclerosis J:174983
premature death J:174983
Itgb3tm1Hyn/Itgb3tm1Hyn
Ldlrtm1Her/Ldlrtm1Her
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 		atherosclerotic lesions J:83615
decreased circulating cholesterol level J:83615
decreased survivor rate J:83615
increased circulating glucose level J:83615
increased susceptibility to induced morbidity/mortality J:83615
Lcattm1Hgc/Lcattm1Hgc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * DBA 		abnormal cholesterol homeostasis J:75567, J:89015
abnormal circulating protein level J:75567
abnormal lipid homeostasis J:75567, J:89015
decreased circulating glucose level J:89015
decreased circulating HDL cholesterol level J:75567, J:89015
decreased circulating insulin level J:89015
decreased circulating LDL cholesterol level J:89015
decreased lipoprotein lipase activity J:89015
normal homeostasis/metabolism phenotype J:75567
increased circulating cholesterol level J:75567
increased circulating triglyceride level J:75567, J:89015
increased circulating VLDL cholesterol level J:75567, J:89015
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129S6/SvEvTac * C57BL/6 		abnormal circulating lipid level J:67282
decreased circulating cholesterol level J:67282
decreased circulating HDL cholesterol level J:67282
Ldlrtm1Her/Ldlr+
Lepob/Lepob
B6.Cg-Lepob Ldlrtm1Her 		increased circulating cholesterol level J:72027
increased circulating HDL cholesterol level J:72027
increased liver cholesterol level J:72027
increased liver triglyceride level J:72027
Ldlrtm1Her/Ldlr+
Tg(H2-K-AKR1B1)1Tj/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2 		hyperglycemia J:100916
increased susceptibility to atherosclerosis J:100916
Ldlrtm1Her/Ldlrtm1Her
Lepob/Lepob
B6.Cg-Lepob Ldlrtm1Her 		abnormal circulating cholesterol level J:72027
atherosclerotic lesions J:72027
hyperlipidemia J:72027
increased circulating cholesterol level J:72027
increased circulating HDL cholesterol level J:72027
increased circulating triglyceride level J:72027
increased liver cholesterol level J:72027
increased liver triglyceride level J:72027
Ldlrtm1Her/Ldlrtm1Her
Lipctm1Unc/Lipctm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal lipid level J:108412
decreased circulating corticosterone level J:108412
increased circulating cholesterol level J:108412
increased circulating HDL cholesterol level J:108412
increased circulating LDL cholesterol level J:108412
Ldlrtm1Her/Ldlrtm1Her
Lipetm1Ishi/Lipetm1Ishi
involves: 129S7/SvEvBrd * C57BL/6J 		increased susceptibility to atherosclerosis J:152385
Ldlrtm1Her/Ldlrtm1Her
Lipetm1Ishi/Lipetm1Ishi
Nceh1tm1Ishi/Nceh1tm1Ishi
involves: 129S7/SvEvBrd * C57BL/6J 		increased susceptibility to atherosclerosis J:152385
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
involves: 129S7/SvEvBrd 		abnormal cholesterol level J:67929
abnormal circulating apolipoprotein E level J:67929
abnormal circulating apolipoprotein level J:67929
increased circulating cholesterol level J:67929
increased circulating LDL cholesterol level J:67929
increased circulating triglyceride level J:67929
increased circulating VLDL cholesterol level J:67929
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		impaired macrophage phagocytosis J:137404
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		abnormal microglial cell physiology J:144185
abnormal response to CNS ischemic injury J:144185
decreased cerebral infarct size J:144185
decreased susceptibility to ischemic brain injury J:144185
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL 		increased circulating cholesterol level J:117317
increased circulating factor VIII level J:117317
increased circulating triglyceride level J:117317
increased circulating von Willebrand factor level J:117317
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL 		abnormal circulating apolipoprotein level J:67929
increased circulating cholesterol level J:67929
increased circulating LDL cholesterol level J:67929
increased circulating triglyceride level J:67929
increased circulating VLDL cholesterol level J:67929
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Tagln-cre)1Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL 		abdominal aorta aneurysm J:82871
abnormal aorta elastic tissue morphology J:82871
aortic aneurysm J:82871
artery occlusion J:82871
atherosclerotic lesions J:82871
dilated aorta J:82871
normal homeostasis/metabolism phenotype J:82871
increased aorta wall thickness J:82871
increased susceptibility to atherosclerosis J:82871
increased vascular smooth muscle cell proliferation J:82871
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Vldlrtm1Her/Vldlrtm1Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL 		increased circulating factor VIII level J:117317
Ldlrtm1Her/Ldlrtm1Her
Lrpap1tm1Her/Lrpap1tm1Her
involves: 129S7/SvEvBrd * C57BL/6J 		abnormal lipid level J:43736
increased circulating cholesterol level J:43736
increased circulating triglyceride level J:43736
Ldlrtm1Her/Ldlrtm1Her
Magi1Gt(OST33326)Lex/Magi1+
involves: 129S5/SvEvBrd * C57BL/6 		decreased susceptibility to atherosclerosis J:278456
Ldlrtm1Her/Ldlrtm1Her
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal macrophage derived foam cell morphology J:142788
arteriosclerosis J:142788
decreased macrophage cell number J:142788
increased circulating cholesterol level J:142788
Ldlrtm1Her/Ldlrtm1Her
Mobq5CAST/EiJ/Mobq5CAST/EiJ
B6.CAST-Mobq5CAST/EiJ 		abnormal circulating VLDL cholesterol level J:116503
decreased circulating cholesterol level J:116503
decreased circulating HDL cholesterol level J:116503
decreased circulating LDL cholesterol level J:116503
Ldlrtm1Her/Ldlrtm1Her
Mobq6CAST/EiJ/Mobq6CAST/EiJ
B6.CAST-Mobq6CAST/EiJ 		abnormal food intake J:116503
decreased circulating cholesterol level J:116503
decreased circulating HDL cholesterol level J:116503
decreased circulating LDL cholesterol level J:116503
decreased circulating VLDL cholesterol level J:116503
decreased susceptibility to atherosclerosis J:116503
decreased susceptibility to diet-induced obesity J:116503
improved glucose tolerance J:116503
Ldlrtm1Her/Ldlrtm1Her
Nceh1tm1Ishi/Nceh1tm1Ishi
involves: 129S7/SvEvBrd * C57BL/6J 		increased susceptibility to atherosclerosis J:152385
Ldlrtm1Her/Ldlrtm1Her
Npc1m1N/Npc1m1N
involves: 129S7/SvEvBrd * BALB/c 		abnormal CNS glial cell morphology J:126474
abnormal Purkinje cell axon morphology J:126474
decreased brain cholesterol level J:130969
decreased corpus callosum size J:126474
decreased Purkinje cell number J:126474
increased cholesterol level J:130969
increased circulating LDL cholesterol level J:104996, J:130969
increased liver cholesterol level J:130969
increased lung cholesterol level J:130969
premature death J:130969
Ldlrtm1Her/Ldlrtm1Her
Npc1m1N/Npc1m1N
involves: 129S7/SvEvBrd * BALB/c * C57BL/6 		increased liver weight J:100351
premature death J:100351
Ldlrtm1Her/Ldlrtm1Her
Nr0b2tm1.1Mjev/Nr0b2tm1.1Mjev
involves: 129S/SvEvBrd * 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		decreased circulating LDL cholesterol level J:149005
normal homeostasis/metabolism phenotype J:149005
increased circulating HDL cholesterol level J:149005
Ldlrtm1Her/Ldlrtm1Her
Nr1h3tm1.1Djm/Nr1h3tm1.1Djm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * DBA 		abnormal cholesterol homeostasis J:184536
decreased circulating cholesterol level J:184536
decreased circulating triglyceride level J:184536
decreased physiological sensitivity to xenobiotic J:184536
increased liver cholesterol level J:184536
increased susceptibility to atherosclerosis J:184536
Ldlrtm1Her/Ldlrtm1Her
Nr5a2tm1Sjns/Nr5a2tm1Sjns
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * C57BL/6J * DBA 		abnormal feces lipid level J:215556
abnormal sterol level J:215556
normal cardiovascular system phenotype J:215556
Ldlrtm1Her/Ldlrtm1Her
Nr5a2tm3.1Sjns/Nr5a2tm3.1Sjns
involves: 129S7/SvEvBrd * C57BL/6J * C57BL/6N 		abnormal bile secretion J:215556
abnormal cholesterol homeostasis J:215556
decreased cholesterol level J:215556
decreased circulating LDL cholesterol level J:215556
decreased circulating triglyceride level J:215556
decreased susceptibility to atherosclerosis J:215556
increased liver cholesterol level J:215556
Ldlrtm1Her/Ldlrtm1Her
Olr1tm1Meht/Olr1tm1Meht
involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 		decreased circulating HDL cholesterol level J:130794
decreased susceptibility to atherosclerosis J:130794
increased circulating interleukin-10 level J:130794
increased circulating LDL cholesterol level J:130794
increased circulating VLDL cholesterol level J:130794
Ldlrtm1Her/Ldlrtm1Her
Pcsk9tm1.2Prat/Pcsk9tm1.2Prat
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ 		increased circulating LDL cholesterol level J:169834
Ldlrtm1Her/Ldlrtm1Her
Pfn1tm1Wit/Pfn1+
B6.129S-Ldlrtm1Her Pfn1tm1Wit 		atherosclerotic lesions J:140294
impaired macrophage chemotaxis J:140294
prenatal lethality, incomplete penetrance J:140294
Ldlrtm1Her/Ldlrtm1Her
Pla2g12ars36523879-C/Pla2g12ars36523879-C
FVB.Cg-Pla2g12ars36523879-C Ldlrtm1Her 		increased susceptibility to diet-induced aortic fatty streak lesions J:290574
Ldlrtm1Her/Ldlrtm1Her
Pparatm1Gonz/Pparatm1Gonz
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		decreased lean body mass J:84844
normal homeostasis/metabolism phenotype J:84844
increased total body fat amount J:84844
Ldlrtm1Her/Ldlrtm1Her
Scarb1tm1Dhu/Scarb1tm1Dhu
involves: 129S4/SvJae * BALB/c * C57BL/6J 		atherosclerotic lesions J:62371
Ldlrtm1Her/Ldlrtm1Her
Scd1ab-2J/Scd1ab-2J
B6.Cg-Ldlrtm1Her Scd1ab-2J 		abnormal circulating cholesterol level J:130278
abnormal epididymal fat pad morphology J:130278
abnormal fat pad morphology J:130278
abnormal lipid level J:130278
abnormal triglyceride level J:130278
abnormal uterine fat pad morphology J:130278
decreased circulating triglyceride level J:130278
decreased circulating VLDL cholesterol level J:130278
decreased circulating VLDL triglyceride level J:130278
decreased liver triglyceride level J:130278
decreased percent body fat/body weight J:130278
normal homeostasis/metabolism phenotype J:130278
increased food intake J:130278
normal liver/biliary system phenotype J:130278
slow postnatal weight gain J:130278
Ldlrtm1Her/Ldlrtm1Her
Scd1ab-J/Scd1ab-J
B6.Cg-Ldlrtm1Her Scd1ab-J 		abnormal epididymal fat pad morphology J:130278
abnormal fat pad morphology J:130278
abnormal lipid level J:130278
abnormal uterine fat pad morphology J:130278
decreased circulating cholesterol level J:130278
decreased circulating triglyceride level J:130278
decreased circulating VLDL cholesterol level J:130278
decreased circulating VLDL triglyceride level J:130278
decreased liver triglyceride level J:130278
decreased percent body fat/body weight J:130278
normal homeostasis/metabolism phenotype J:130278
increased food intake J:130278
normal liver/biliary system phenotype J:130278
slow postnatal weight gain J:130278
Ldlrtm1Her/Ldlrtm1Her
Serpine1tm1Mlg/Serpine1tm1Mlg
B6.129S-Serpine1tm1Mlg Ldlrtm1Her 		atherosclerotic lesions J:61287
increased circulating cholesterol level J:61287
Ldlrtm1Her/Ldlrtm1Her
Soat1tm1Far/Soat1tm1Far
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J 		abnormal brain morphology J:61147
abnormal cerebellum morphology J:61147
abnormal dermal layer morphology J:61147
atherosclerotic lesions J:61147
decreased circulating cholesterol level J:61147
skin edema J:61147
skin inflammation J:61147
skin lesions J:61147
thick skin J:61147
xanthoma J:61147
Ldlrtm1Her/Ldlrtm1Her
Tbx21tm1Glm/Tbx21tm1Glm
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 		abnormal interleukin secretion J:96110
abnormal susceptibility to atherosclerosis J:96110
decreased IgG level J:96110
decreased interferon-gamma secretion J:96110
increased circulating cholesterol level J:96110
increased IgM level J:96110
Ldlrtm1Her/Ldlrtm1Her
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
B6.129-Ldlrtm1Her Tcra-Jtm1Tgi 		decreased interferon-gamma secretion J:140276
decreased susceptibility to atherosclerosis J:140276
Ldlrtm1Her/Ldlrtm1Her
Tg(APOC1)1Lmh/?
involves: 129S7/SvEvBrd * C57BL/6 		increased circulating cholesterol level J:65146
increased circulating triglyceride level J:65146
increased circulating VLDL cholesterol level J:65146
increased circulating VLDL triglyceride level J:65146
Ldlrtm1Her/Ldlrtm1Her
Tg(APOC3)3707Bres/?
involves: 129S7/SvEvBrd * C57BL/6J * CBA/J 		atherosclerotic lesions J:37861
increased circulating LDL cholesterol level J:37861
increased circulating VLDL cholesterol level J:37861
Ldlrtm1Her/Ldlrtm1Her
Tg(APOC3)3707Bres/?
Tg(Mt1-CETP)#Tall/?
involves: 129S7/SvEvBrd * C57BL/6J * CBA/J 		decreased circulating HDL cholesterol level J:37861
increased circulating LDL cholesterol level J:37861
increased circulating triglyceride level J:37861
increased circulating VLDL cholesterol level J:37861
Ldlrtm1Her/Ldlrtm1Her
Tg(APOM)NCchr/0
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * CBA 		abnormal cholesterol homeostasis J:130647
decreased circulating triglyceride level J:130647
decreased susceptibility to atherosclerosis J:130647
Ldlrtm1Her/Ldlrtm1Her
Tg(APPSWE)2576Kha/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL 		abnormal long-term spatial reference memory J:114480
abnormal response to new environment J:114480
abnormal spatial learning J:114480
amyloid beta deposits J:114480
amyloidosis J:114480
decreased anxiety-related response J:114480
hyperactivity J:114480
increased circulating cholesterol level J:114480
increased circulating LDL cholesterol level J:114480
Ldlrtm1Her/Ldlrtm1Her
Tg(CMV-Serpine1)1Dgi/0
B6.Cg-Ldlrtm1Her Tg(CMV-Serpine1)1Dgi 		atherosclerotic lesions J:61287
increased circulating cholesterol level J:61287
Ldlrtm1Her/Ldlrtm1Her
Tg(H2-K-AKR1B1)1Tj/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2 		abnormal circulating cholesterol level J:100916
abnormal macrophage physiology J:100916
hyperglycemia J:100916
increased susceptibility to atherosclerosis J:100916
Ldlrtm1Her/Ldlrtm1Her
Tg(Il1rn)1Dih/Tg(Il1rn)1Dih
involves: 129S7/SvEvBrd * C57BL/6 * CBA 		decreased susceptibility to atherosclerosis J:76336
increased circulating cholesterol level J:76336
increased circulating triglyceride level J:76336
Ldlrtm1Her/Ldlrtm1Her
Tlr2tm1Kir/Tlr2tm1Kir
B6.129-Tlr2tm1Kir Ldlrtm1Her 		abnormal cellular extravasation J:131783
atherosclerotic lesions J:102502, J:131783
decreased circulating cholesterol level J:102502
decreased tumor necrosis factor secretion J:131783
increased body weight J:102502, J:131783
Ldlrtm1Her/Ldlrtm1Her
Vcam1tm1Dmil/Vcam1tm1Dmil
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		decreased susceptibility to atherosclerosis J:69597
Ldlrtm1Her/Ldlrtm1Her
Vwftm1Wgr/Vwftm1Wgr
B6.129S-Vwftm1Wgr Ldlrtm1Her 		decreased susceptibility to atherosclerosis J:106677
impaired leukocyte tethering or rolling J:106677
Ldlrtm2(AFP)Alb/Ldlrtm2(AFP)Alb
involves: 129S7/SvEvBrd * C57BL/6J 		no abnormal phenotype detected J:132096
Soat1tm1Ishi/Soat1tm1Ishi
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6 		abnormal lipid homeostasis J:63468
dry eyes J:63468
increased circulating cholesterol level J:63468
Meibomian gland atrophy J:63468
xanthoma J:63468
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory